Susan Bobulsky, Adaptive Biotechnologies Corp's Chief Commercial Officer for the company’s Minimal Residual Disease (MRD) business, sold 41,338 shares of common stock on March 11, 2026. The shares were disposed of at $13.17 apiece, producing a total transaction value of $544,421.
Adaptive Biotechnologies is listed on the Nasdaq under the ticker ADPT. The sale occurred against a backdrop of recent share-price movement: the stock fell 11% during the past week, though it remains 81% higher over the previous 12 months.
Following the disposition, Bobulsky directly holds 427,775 shares of Adaptive Biotechnologies. Company filings indicate the sale was completed to satisfy tax withholding obligations associated with the vesting of Restricted Stock Units. Under Adaptive Biotechnologies’ equity incentive plans, such tax obligations are required to be funded by a "sell to cover" transaction.
Investors also received fresh financial data from Adaptive Biotechnologies in recent reporting. The company’s fourth-quarter 2025 results exceeded analyst expectations on both the bottom and top lines. Reported earnings per share were -$0.09, better than the -$0.18 consensus, representing a 50% positive surprise relative to the forecast. Quarterly revenue totaled $71.7 million, outpacing the expected $59.33 million and reflecting a 20.85% increase.
Analysts responded to the stronger results and updated guidance. BTIG raised its price target for Adaptive Biotechnologies to $22.00 from $21.00 while keeping a Buy rating, citing robust growth within the company’s core MRD business. That MRD unit grew 54% year over year in the fourth quarter and contributed to a 46% year-over-year revenue increase for the full year. TD Cowen raised its price target to $21.00 following the company’s pre-announced fourth-quarter results and guidance, and Piper Sandler reiterated an Overweight rating with a $20.00 price target.
Collectively, the insider sale, recent share-price fluctuation, and the company’s outperformance in the quarter illustrate active dynamics in Adaptive Biotechnologies’ stock and its MRD-focused business line. The documented sale was a procedural step to meet tax obligations arising from RSU vesting rather than an unsolicited secondary market disposition unrelated to compensation-related requirements.
Summary
Susan Bobulsky sold 41,338 shares of Adaptive Biotechnologies on March 11, 2026, at $13.17 per share for $544,421 to cover tax withholding tied to RSU vesting. The stock experienced an 11% decline over the previous week but is up 81% year over year. Adaptive reported fourth-quarter 2025 EPS of -$0.09 and revenue of $71.7 million, both ahead of expectations, prompting several analyst price-target increases and continued positive coverage focused on MRD revenue strength.